3-(heteroaryl-oxy)-2-alkyl-1-aza-bicyclo alkyl derivatives as alpha.7-NACHR ligands for the treatment of CNS diseases

Details for Australian Patent Application No. 2005261866 (hide)

Owner Novartis AG

Inventors Troxler, Thomas J.; Frederiksen, Matthias; Feuerbach, Dominik; Roy, Bernard Lucien; Hurth, Konstanze

Agent Davies Collison Cave

Pub. Number AU-B-2005261866

PCT Pub. Number WO2006/005608

Priority 0415746.7 14.07.04 GB

Filing date 13 July 2005

Wipo publication date 19 January 2006

Acceptance publication date 10 December 2009

International Classifications

C07D 453/02 (2006.01) Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids

C07D 487/08 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

1 February 2007 PCT application entered the National Phase

  PCT publication WO2006/005608 Priority application(s): WO2006/005608

10 December 2009 Application Accepted

  Published as AU-B-2005261866

8 April 2010 Corrigenda

  Applications Accepted - Name Index Under the name Novartis AG, Application No. 2005261866, under INID (72) remove the co-inventor Troxler, Thomas J.

15 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005261867-Substituted oxindol derivatives and medicaments containing the same

2005261862-Biochemical synthesis of 1,4-butanediamine